文献速递免疫规划传染病防控与疫情报告

不同出生队列接种乙肝疫苗后抗-HBs抗体滴度差异的横断面研究

Variable anti-HBs antibody titers in vaccinated birth cohorts - A cross-sectional population-based study.
PubMed 文献 · Vaccine · 2020-09-19

该研究在罗马尼亚Cluj-Napoca教学医院纳入2014年4月至2018年12月检测抗-HBs滴度的2963名门诊和住院患者,比较不同出生队列的抗体水平。结果显示1995-2006年出生、出生后接种疫苗的队列保护性滴度比例(41.3% >10 mIU/mL)显著低于其他队列,而未接种队列为44.8%。结论支持乙肝疫苗在初免后二十年仍有长期保护证据,不支持加强针。

要点

  • 1995-2006年出生接种队列保护性抗-HBs比例仅41.3%,低于其他队列。
  • 出生后接种疫苗的2007年后出生队列保护性比例为67.0%。
  • 未接种队列保护性比例为44.8%,可能源于自限性乙肝感染。

核心结论

  • 乙肝疫苗初免后二十年仍有长期保护证据,不支持加强针。
  • 需进一步研究评估一般人群和特殊人群是否需要加强剂量。

研究设计与样本

  • 横断面人群研究,纳入罗马尼亚Cluj-Napoca传染病教学医院2014年4月至2018年12月检测抗-HBs滴度的门诊(78.5%)和住院患者,共2963人,平均年龄31.0±14.2岁,女性64.1%。

主要发现

  • 1995-2006年出生、出生后接种疫苗队列(n=424,3剂覆盖率>90%)保护性滴度(>10 mIU/mL)比例为41.3%,显著低于其他队列。
  • 2007年后出生、出生时接种队列保护性比例为67.0%(n=106)。
  • 1991-1994年出生、9岁时补种队列保护性比例为74.3%(n=847)。
  • 1986-1990年出生、18岁时补种队列保护性比例为71.3%(n=543)。
  • 未接种队列(n=1043,平均年龄45.5±12.4岁)保护性比例为44.8%,可能源于自限性乙肝感染。

关键数值与推荐

  • 保护性抗-HBs滴度定义为>10 mIU/mL。
  • 1995-2006年出生接种队列保护性比例41.3%,2007年后出生接种队列67.0%,1991-1994年出生补种队列74.3%,1986-1990年出生补种队列71.3%,未接种队列44.8%。
  • 检测的47名婴儿(未纳入主研究)保护性比例为88.9%。

临床怎么用

  • 乙肝疫苗初免后二十年无需常规加强针。
  • 应关注不同出生队列抗体水平的差异,尤其1995-2006年出生接种队列。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After the introduction of hepatitis B (HB) vaccination in 1995 in newborns, two catch-up campaigns targeted unvaccinated 9 year old in 2000-2003 (born 1991-1994) and the 18 year old in 2004-2008 (born 1986-1990), resulting in several birth-cohorts. Our objective was to assess the anti-HBs titers in each birth-cohort. METHODS: We included all outpatients (78.5%) and hospitalized patients with measured anti-HBs antibody titers in the Teaching Hospital of Infectious Diseases, Cluj-Napoca, Romania, during April 2014 - December 2018 (without HB history). We compared the anti-HBs titers in all birth-cohorts using the Lexis surfaces (titers by age, time period and cohort patterns). We also evaluated the number of acute HB in the corresponding inpatient birth-cohorts and special groups. RESULTS: We included 2963 participants, mean age = 31.0 ± 14.2, 64.1% women. The birth-cohort 1995-2006, vaccinated after delivery (n = 424, 3-dose HB vaccine coverage > 90%), had significantly lower protective titers (41.3% >10 mIU/mL) compared to the other birth-cohorts: born after 2007 (also vaccinated at birth, 67.0%, n = 106), 1991-1994 (age 9, 74.3%, n = 847), 1986-1990 (age 18, 71.3%, n = 543). In the unvaccinated cohort (n = 1043, mean age = 45.5 ± 12.4) protective titers were found in 44.8%, probably after self-limited HB infection. Concordant results were found using the proportion of patients with detectable or robust titers, and median or geometric mean titers. Four breakthrough acute HB infections were hospitalized of the corresponding vaccinated cohorts (birth years 1988, 1990, 1995, 1996). Data on a few tested infants (n = 47, not included in the main study) demonstrated good protection, 88.9%. CONCLUSIONS: Our study demonstrated the long-term evidence of protection of HBV vaccine at two decades following the primary immunization and a booster seems unsupported. Further studies should be done to assess the need of a booster dose within the general population and special groups.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Istrate A, Azoicăi D, Almaş A, et al. Variable anti-HBs antibody titers in vaccinated birth cohorts - A cross-sectional population-based study. Vaccine. 2020. PMID: 32962805. doi:10.1016/j.vaccine.2020.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。